A citation-based method for searching scientific literature

Mathieu Hatt, David Groheux, Antoine Martineau, Marc Espié, Elif Hindié, Sylvie Giacchetti, Anne de Roquancourt, Dimitris Visvikis, Catherine Cheze-Le Rest. J Nucl Med 2013
Times Cited: 59







List of co-cited articles
363 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.
David Groheux, Sylvie Giacchetti, Jean-Luc Moretti, Raphael Porcher, Marc Espié, Jacqueline Lehmann-Che, Anne de Roquancourt, Anne-Sophie Hamy, Caroline Cuvier, Laetitia Vercellino,[...]. Eur J Nucl Med Mol Imaging 2011
235
32

Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
David Groheux, Mathieu Hatt, Elif Hindié, Sylvie Giacchetti, Patricia de Cremoux, Jacqueline Lehmann-Che, Antoine Martineau, Michel Marty, Caroline Cuvier, Catherine Cheze-Le Rest,[...]. Cancer 2013
42
45

Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
Jörg Schwarz-Dose, Michael Untch, Reinhold Tiling, Stefanie Sassen, Sven Mahner, Steffen Kahlert, Nadia Harbeck, Annette Lebeau, Winfried Brenner, Markus Schwaiger,[...]. J Clin Oncol 2009
153
27

FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Bas B Koolen, Kenneth E Pengel, Jelle Wesseling, Wouter V Vogel, Marie-Jeanne T F D Vrancken Peeters, Andrew D Vincent, Kenneth G A Gilhuijs, Sjoerd Rodenhuis, Emiel J Th Rutgers, Renato A Valdés Olmos. Breast 2013
53
30

Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis.
Yuting Wang, Chengpeng Zhang, Jianjun Liu, Gang Huang. Breast Cancer Res Treat 2012
85
27

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
Richard L Wahl, Heather Jacene, Yvette Kasamon, Martin A Lodge. J Nucl Med 2009
27

Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
Caroline Rousseau, Anne Devillers, Christine Sagan, Ludovic Ferrer, Boumédiène Bridji, Loïc Campion, Myriam Ricaud, Emmanuelle Bourbouloux, Isabelle Doutriaux, Martine Clouet,[...]. J Clin Oncol 2006
208
27

HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
D Groheux, S Giacchetti, M Hatt, M Marty, L Vercellino, A de Roquancourt, C Cuvier, F Coussy, M Espié, E Hindié. Br J Cancer 2013
40
40

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012
23

Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse.
David Groheux, Elif Hindié, Sylvie Giacchetti, Marc Delord, Anne-Sophie Hamy, Anne de Roquancourt, Laetitia Vercellino, Nathalie Berenger, Michel Marty, Marc Espié. J Nucl Med 2012
62
23

18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Geraldine Gebhart, Cristina Gámez, Eileen Holmes, Javier Robles, Camilo Garcia, Montserrat Cortés, Evandro de Azambuja, Karine Fauria, Veerle Van Dooren, Gursel Aktan,[...]. J Nucl Med 2013
88
23

Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes.
O Humbert, A Berriolo-Riedinger, J M Riedinger, B Coudert, L Arnould, A Cochet, C Loustalot, P Fumoleau, F Brunotte. Ann Oncol 2012
62
22

Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
Ukihide Tateishi, Mototaka Miyake, Tomoaki Nagaoka, Takashi Terauchi, Kazunori Kubota, Takayuki Kinoshita, Hiromitsu Daisaki, Homer A Macapinlac. Radiology 2012
89
22


Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
22

Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.
Bas B Koolen, Kenneth E Pengel, Jelle Wesseling, Wouter V Vogel, Marie-Jeanne T F D Vrancken Peeters, Andrew D Vincent, Kenneth G A Gilhuijs, Sjoerd Rodenhuis, Emiel J Th Rutgers, Renato A Valdés Olmos. Eur J Nucl Med Mol Imaging 2014
38
31

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
20

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.
Alina Berriolo-Riedinger, Claude Touzery, Jean-Marc Riedinger, Michel Toubeau, Bruno Coudert, Laurent Arnould, Christophe Boichot, Alexandre Cochet, Pierre Fumoleau, François Brunotte. Eur J Nucl Med Mol Imaging 2007
129
18

Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
Olivier Humbert, Alina Berriolo-Riedinger, Alexandre Cochet, Mélanie Gauthier, Céline Charon-Barra, Séverine Guiu, Isabelle Desmoulins, Michel Toubeau, Inna Dygai-Cochet, Charles Coutant,[...]. Eur J Nucl Med Mol Imaging 2014
34
32

Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
David Groheux, Mohamed Majdoub, Alice Sanna, Patricia de Cremoux, Elif Hindié, Sylvie Giacchetti, Antoine Martineau, Anne de Roquancourt, Pascal Merlet, Dimitris Visvikis,[...]. Radiology 2015
44
25

HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Olivier Humbert, Alexandre Cochet, Jean-Marc Riedinger, Alina Berriolo-Riedinger, Laurent Arnould, Bruno Coudert, Isabelle Desmoulins, Michel Toubeau, Inna Dygai-Cochet, Séverine Guiu,[...]. Eur J Nucl Med Mol Imaging 2014
38
26

Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim.
David Groheux, Sylvie Giacchetti, Marc Espié, Domenico Rubello, Jean-luc Moretti, Elif Hindié. Eur J Nucl Med Mol Imaging 2011
54
16

Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
David Groheux, Elif Hindié, Marc Delord, Sylvie Giacchetti, Anne-sophie Hamy, Cédric de Bazelaire, Anne de Roquancourt, Laetitia Vercellino, Marie-Elisabeth Toubert, Pascal Merlet,[...]. J Natl Cancer Inst 2012
89
15


Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
David Groheux, Elif Hindié, Sylvie Giacchetti, Anne-Sophie Hamy, Frederique Berger, Pascal Merlet, Anne de Roquancourt, Patricia de Cremoux, Michel Marty, Mathieu Hatt,[...]. Eur J Cancer 2014
37
24

18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Xu Cheng, Yongjun Li, Biao Liu, Zhaoqiang Xu, Lihua Bao, Jie Wang. Acta Radiol 2012
36
22


Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
Lisa K Dunnwald, Julie R Gralow, Georgiana K Ellis, Robert B Livingston, Hannah M Linden, Jennifer M Specht, Robert K Doot, Thomas J Lawton, William E Barlow, Brenda F Kurland,[...]. J Clin Oncol 2008
111
13

18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
Bas B Koolen, Marie-Jeanne T F D Vrancken Peeters, Tjeerd S Aukema, Wouter V Vogel, Hester S A Oldenburg, Jos A van der Hage, Cornelis A Hoefnagel, Marcel P M Stokkel, Claudette E Loo, Sjoerd Rodenhuis,[...]. Breast Cancer Res Treat 2012
85
11

Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer.
Jennifer M Specht, Brenda F Kurland, Susan K Montgomery, Lisa K Dunnwald, Robert K Doot, Julie R Gralow, Georgina K Ellis, Hannah M Linden, Robert B Livingston, Kimberly H Allison,[...]. Clin Cancer Res 2010
50
14

Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy.
B B Koolen, M J T F D Vrancken Peeters, J Wesseling, E H Lips, W V Vogel, T S Aukema, E van Werkhoven, K G A Gilhuijs, S Rodenhuis, E J Th Rutgers,[...]. Eur J Nucl Med Mol Imaging 2012
62
11

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
Julie R Gralow, Harold J Burstein, William Wood, Gabriel N Hortobagyi, Luca Gianni, Gunter von Minckwitz, Aman U Buzdar, Ian E Smith, William F Symmans, Baljit Singh,[...]. J Clin Oncol 2008
256
11

Monitoring primary breast cancer throughout chemotherapy using FDG-PET.
Garry M McDermott, Andrew Welch, Roger T Staff, Fiona J Gilbert, Lutz Schweiger, Scott I K Semple, Tim A D Smith, Andrew W Hutcheon, Iain D Miller, Ian C Smith,[...]. Breast Cancer Res Treat 2007
91
11

Performance of FDG PET/CT in the clinical management of breast cancer.
David Groheux, Marc Espié, Sylvie Giacchetti, Elif Hindié. Radiology 2013
139
11

Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.
D M Sataloff, B A Mason, A J Prestipino, U L Seinige, C P Lieber, Z Baloch. J Am Coll Surg 1995
331
11

18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer.
Joan Duch, David Fuster, Montserrat Muñoz, Pedro Luís Fernández, Pilar Paredes, Montserrat Fontanillas, Flavia Guzmán, Sebastià Rubí, Francisco Juan Lomeña, Francesca Pons. Eur J Nucl Med Mol Imaging 2009
82
11

Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer.
A Gil-Rendo, F Martínez-Regueira, G Zornoza, M J García-Velloso, C Beorlegui, N Rodriguez-Spiteri. Br J Surg 2009
111
11

The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Amandeep Kumar, Rakesh Kumar, Vathalaru Seenu, Sidharatha Datta Gupta, Madhavi Chawla, Arun Malhotra, Sada Nand Mehta. Eur Radiol 2009
65
11

Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
M Schelling, N Avril, J Nährig, W Kuhn, W Römer, D Sattler, M Werner, J Dose, F Jänicke, H Graeff,[...]. J Clin Oncol 2000
392
11


Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer.
Michael Soussan, Fanny Orlhac, Marouane Boubaya, Laurent Zelek, Marianne Ziol, Véronique Eder, Irène Buvat. PLoS One 2014
99
11

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, Jared N Schwartz, Karen L Hagerty, D Craig Allred, Richard J Cote, Mitchell Dowsett, Patrick L Fitzgibbons, Wedad M Hanna, Amy Langer,[...]. J Clin Oncol 2007
10

Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
David Fuster, Joan Duch, Pilar Paredes, Martín Velasco, Montserrat Muñoz, Gorane Santamaría, Montserrat Fontanillas, Francesca Pons. J Clin Oncol 2008
183
10

FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.
Caroline Rousseau, Anne Devillers, Mario Campone, Loïc Campion, Ludovic Ferrer, Christine Sagan, Myriam Ricaud, Boumédiène Bridji, Françoise Kraeber-Bodéré. Eur J Nucl Med Mol Imaging 2011
38
15

The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.
T S Aukema, E J Th Rutgers, W V Vogel, H J Teertstra, H S Oldenburg, M T F D Vrancken Peeters, J Wesseling, N S Russell, R A Valdés Olmos. Eur J Surg Oncol 2010
60
10


Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
10

Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.
Steven M. Larson, Yusuf Erdi, Timothy Akhurst, Madhu Mazumdar, Homer A. Macapinlac, Ronald D. Finn, Cecille Casilla, Melissa Fazzari, Neil Srivastava, Henry W.D. Yeung,[...]. Clin Positron Imaging 1999
400
10

Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.
David A Mankoff, Lisa K Dunnwald, Julie R Gralow, Georgiana K Ellis, Erin K Schubert, Jeffrey Tseng, Thomas J Lawton, Hannah M Linden, Robert B Livingston. J Nucl Med 2003
146
10

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
W Fraser Symmans, Florentia Peintinger, Christos Hatzis, Radhika Rajan, Henry Kuerer, Vicente Valero, Lina Assad, Anna Poniecka, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2007
779
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.